Carebot

AI-based recommender systems to improve efficiency and accuracy of medical imaging diagnostics.

The AI-based tool enables detection and evaluation of prostate cancer on histopathological images. The target market is healthcare facilities, laboratories and clinical institutions involved in the diagnosis and treatment of prostate cancer. The Company has experience in certifying AI-enabled medical devices and the ability to integrate its technology into existing image processing systems. The business model includes two options: royalties and strategic partnerships. The goal is to implement the product in the domestic market and then expand to international markets.

Unique selling points:

• Automatic detection of prostate cancer using AI, accuracy and reliability in diagnosis. Contribution to faster detection and diagnosis through automatic analysis of large amounts of data.
• Reducing error rates, improving the quality of diagnoses and outcomes for patients.
• Partnerships with leading hospitals and PACS providers in the Czech Republic.
• Effective reduction of variability in evaluation and human error in the evaluation of histopathological specimens.

Incubation